Jpmorgan Chase & CO Edgewise Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 91,368 shares of EWTX stock, worth $1.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
91,368
Previous 124,435 26.57%
Holding current value
$1.34 Million
Previous $3.32 Million 39.49%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$22.0 - $30.03 $727,474 - $993,002
-33,067 Reduced 26.57%
91,368 $2.01 Million
Q4 2024

Feb 12, 2025
SELL
$26.63 - $36.62 $907,310 - $1.25 Million
-34,071 Reduced 21.5%
124,435 $3.32 Million
Q3 2024

Dec 26, 2024
BUY
$15.88 - $29.5 $1.5 Million - $2.78 Million
94,147 Added 146.28%
158,506 $4.23 Million
Q3 2024

Nov 08, 2024
BUY
$15.88 - $29.5 $1.5 Million - $2.78 Million
94,147 Added 146.28%
158,506 $4.23 Million
Q2 2024

Dec 26, 2024
SELL
$15.08 - $21.23 $1.42 Million - $2 Million
-94,147 Reduced 59.4%
64,359 $1.16 Million
Q2 2024

Aug 12, 2024
BUY
$15.08 - $21.23 $324,612 - $456,996
21,526 Added 50.26%
64,359 $1.16 Million
Q1 2024

Dec 26, 2024
SELL
$9.25 - $19.97 $1.07 Million - $2.31 Million
-115,673 Reduced 72.98%
42,833 $781,000
Q1 2024

May 10, 2024
BUY
$9.25 - $19.97 $25,622 - $55,316
2,770 Added 6.91%
42,833 $781,000
Q4 2023

Dec 26, 2024
SELL
$5.51 - $12.1 $652,620 - $1.43 Million
-118,443 Reduced 74.72%
40,063 $438,000
Q4 2023

Feb 12, 2024
SELL
$5.51 - $12.1 $2,429 - $5,336
-441 Reduced 1.09%
40,063 $438,000
Q3 2023

Nov 14, 2023
BUY
$5.73 - $7.69 $28,225 - $37,880
4,926 Added 13.85%
40,504 $232,000
Q2 2023

Aug 11, 2023
BUY
$5.71 - $10.29 $23,970 - $43,197
4,198 Added 13.38%
35,578 $275,000
Q1 2023

May 18, 2023
BUY
$6.66 - $11.33 $193,379 - $328,977
29,036 Added 1238.74%
31,380 $209,000
Q1 2023

May 11, 2023
SELL
$6.66 - $11.33 $146,340 - $248,954
-21,973 Reduced 90.36%
2,344 $15,000
Q4 2022

Feb 13, 2023
BUY
$7.58 - $11.08 $34,261 - $50,081
4,520 Added 22.83%
24,317 $217,000
Q3 2022

Nov 14, 2022
SELL
$8.08 - $13.58 $10,600 - $17,816
-1,312 Reduced 6.22%
19,797 $195,000
Q2 2022

Aug 11, 2022
SELL
$5.67 - $9.87 $34,343 - $59,782
-6,057 Reduced 22.3%
21,109 $168,000
Q1 2022

May 11, 2022
BUY
$9.1 - $18.97 $46,919 - $97,809
5,156 Added 23.43%
27,166 $263,000
Q4 2021

Feb 10, 2022
BUY
$14.41 - $22.41 $209,391 - $325,639
14,531 Added 194.29%
22,010 $337,000
Q3 2021

Nov 12, 2021
BUY
$14.11 - $24.1 $105,528 - $180,243
7,479 New
7,479 $124,000

Others Institutions Holding EWTX

# of Institutions
191
Shares Held
118M
Call Options Held
54.3K
Put Options Held
70.1K
View Full List

About Edgewise Therapeutics, Inc.

EWTX Quotes by TradingView
  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $929M
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email